Among them, the PD‐L1 expression is used in clinic for several cancer types, and some immunohistochemistry (IHC) assays to quantify PD‐L1 expression in tumour tissues have been approved by the U.S. Food and Drug Administration (FDA).5 The gene discussed is CD274; the disease is neoplasm.